The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull.

Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting turns. Some experiences, like witnessing one of your portfolio companies transform the standard of care for patients,

Continue reading The Business of Biotech: What to Do When the S*#t Hits the Fan